You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 61 No. 1, January 2004 TABLE OF CONTENTS
  Archives
  •  Online Features
  This Month in Archives of Neurology
 This Article
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

This Month in Archives of Neurology

Arch Neurol. 2004;61:18-19.

Targets of Paraneoplastic Antibodies

Robert Darnell (SEE ARTICLE) has pioneered the use of paraneoplastic antibodies to screen complementary DNA (cDNA) expression libraries for clones of DNA that encode the target onconeural antigens. The paraneoplastic neurologic disorder (PND) cDNAs have allowed new clinical studies, in which the disease and its pathophysiologic mechanisms have given fresh insights into tumor immunity and autoimmune brain disease. He reviews the molecular mechanisms underlying the major PNDs and associated antigens. Insights into potential therapies for the major PNDs and related cancers are outlined in this elegant and insightful review.


Parkinsonism Masking as Spinocerebellar Ataxia Type 2

Lu and colleagues (SEE ARTICLE) report the presence of parkinsonism in families with spinocerebellar ataxia type 2 (SCA2) in Taiwan. They found expanded CAG repeats of SCA2 in 7 patients from 4 parkinsonian families (about 10% of their familial parkinsonian series). Thus, SCA2 can manifest parkinsonism as a major feature and is associated with a lower abnormal range of CAG repeat length and with a late age at onset. Spinocerebellar ataxia type 2 should be considered as a genetic basis for familial parkinsonism. Editorial perspective is provided by Katrina Gwinn-Hardy, MD.


Stenting NASCET-Ineligible Internal Carotid Artery Stenosis

Linfante and colleagues (SEE ARTICLE) studied 23 patients with extracranial carotid artery stenting (CAS) who were otherwise ineligible for surgery according to the criteria of the North America Symptomatic Carotid Endarterectomy Trial (NASCET). The latest generation self-expanding stents were used. Carotid artery stenting was successful in all cases, with an average residual stenosis of less than 20%. Thus, extracranial CAS using the latest generation self-expanding stents is a valid alternative treatment in high-risk or NASCET-ineligible patients.


Ganglionic Acetylcholine Receptor Antibody and Autonomic Neuropathy

Sandroni and colleagues (SEE ARTICLE) compared patients who were seropositive and seronegative for ganglionic acetylcholine receptor (AChr) autoantibodies. The seropositive group had a subacute onset, with significant overrepresentation of abnormal pupillary responses, sicca complex, and lower gastrointestinal tract dysautonomia compared with the seronegative group. Their observations support the view that ganglionic AChR antibodies are diagnostically and pathophysiologically important.


Novel Mutations in the Spastin Gene

Chinese patients with hereditary spastic paraplegia were studied for mutations in the spastin gene (SPG4) by Tang and colleagues (SEE ARTICLE) in China. Three novel mutations were detected in 4 affected individuals, including 2 missense mutations (T1258A and A1293G) and 1 deletion mutation (1668-1670delCTA). This is the first report of SPG4 mutations in China.


Characteristics of Mild Cognitive Impairment

The essential baseline characteristics of mild cognitive impairment (MCI) were defined by Grundman et al (SEE ARTICLE) to differentiate patients with MCI from patients with Alzheimer disease (AD) and normal elderly controls. They found that patients with MCI are more impaired in memory tasks compared with normal controls, but they have less severe impairments in other cognitive domains. Patients with MCI had hippocampal volumes that were intermediate between normal controls and AD patients. They conclude that AD prevention trials with MCI patients appear to be a promising approach for detecting, intervening, and delaying clinical AD while the disease is still in a transitional clinical stage.


Homocysteine and Magnetic Resonance Imaging Associations

In the Cardiovascular Health Study, 622 elderly participants without a history of transient ischemic attack or stroke were studied by Longstreth et al (SEE ARTICLE) for homocysteine levels and findings on brain magnetic resonance imaging (MRI). An association was seen for an MRI pattern combining infarcts and a high white matter grade. Their findings support the view that elevated total homocysteine levels may cause subcortical vascular encephalopathy with diffuse white matter lesions and lacunes.


Cognitive Reserve and Positron Emission Tomography Activation in Alzheimer Disease

Afunctional definition of cognitive reserve (CR) is the ability of an individual to cope with advancing brain disease so that he or she remains free of symptoms. Scarmeas and colleagues (SEE ARTICLE) investigated CR-mediated differential brain activation in patients with Alzheimer disease (AD) compared with healthy elderly controls. Using H215O positron emission tomography, they imaged 12 AD patients and 17 healthy controls while the subjects performed a serial recognition memory task. Evidence is presented to support the concept that CR provides incremental abilities to delay or modify cognitive loss in AD.


Vitamins C and E Together Reduce Alzheimer Disease

The effect of vitamins C and E to reduce the risk of Alzheimer disease (AD) was studied by Zandi and colleagues (SEE ARTICLE) . They found that the use of vitamin C and E supplements in combination was associated with reduced AD prevalence and incidence. Antioxidant supplements merit further study as agents for the primary prevention of AD.


High-Frequency Stimulation of the Subthalamic Nucleus and Parkinson Disease

Welter et al (SEE ARTICLE) studied the effects of high-frequency subthalamic nucleus (STN) stimulation on the neuronal activity of STN neurons in patients with Parkinson disease (PD) as a means of defining the effectiveness of this therapeutic modality. They found that stimulation at a frequency greater than 40 Hz applied within the STN significantly decreased the firing frequency and increased the burst-like activity in the firing pattern of STN neurons. Their evidence supports the view that the beneficial effects of high stimulation result from a change in the firing pattern of cellular discharge and a blockade of the spontaneous overactivity of STN neurons.


Effects of subthalamic nucleus (STN) high-frequency stimulation on neuronal activity in the structure (140 Hz, 60 microseconds, 2 mA). A, High-frequency stimulation applied within the STN: mean firing rate of 21 cells before, during, and after stimulation (left); distribution of the firing pattern of these 21 cells before, during, and after stimulation (right). B, High-frequency stimulation applied above the STN: mean firing rate of 8 cells before, during, and after stimulation (left); distribution of the firing pattern of these 8 cells before, during, and after stimulation (right).



Impaired Daytime Sleep and Wakefulness in Patients With Parkinson Disease

Total dopaminergic drug dose rather than the specific dopamine agonist used is the best predictor of daytime sleepiness in patients with Parkinson disease who are receiving dopamine agonist therapy as reported by Razmy and colleagues (SEE ARTICLE) . Polysomnographic monitoring for impaired daytime sleep latency is of clinical diagnostic value in evaluating this adverse effect of therapy.


Multiminicores in Malignant Hyperthermia

Guis and colleagues (SEE ARTICLE) report a family with malignant hyperthermia (MH). Multiminicores on muscle biopsy were observed in MH-susceptible patients. These multiminicore lesions may be secondary to mutations in the ryanodine receptor gene. As a consequence, these patients must be distinguised from patients with multiminicore disease and from other MH-susceptible patients for whom multiminicores are not observed. Editorial perspective is provided by Katherine D. Mathews, MD.







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.